Mirvie
South San Francisco, US · Delaware corporation · 6 known investors
Mirvie develops an RNA-based platform for early detection of pregnancy complications, enabling proactive intervention before complications become critical. The platform serves pregnant women and their healthcare providers to improve maternal and fetal health outcomes.
Founders & leadership
Investors · 6
Reported raises · per SEC filings
Form D private placements▶$23.7MraisedAug 2025 · 25 investors · OtherRule 506(b)
▶$23.7MraisedAug 2025 · 25 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Lisa IversonDirector
- Ursheet ParikhDirector
- Naomi KelmanDirector
- Min CuiDirector
- Maneesh JainExecutive Officer, Director, Promoter
- Stanley LapidusDirector
- Samir KaulDirector
- Stephen QuakeDirector
- Offering amount
- $30M
- Amount sold
- $23.7M
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
- Mirvie Inc. raises $23.7M: offering $30M: Form Dainvest.com · 2025
- Biotech Company Mirvie Raises $60M for Its RNA Platform Focused on Early Prediction of Pregnancy Complications | Femtech Insiderfemtechinsider.com · 2022
- Mirvie Raises $60 Million For Blood Test To Predict Pregnancy Complicationsforbes.com · 2022
- Wilson Sonsini Advises Mirvie on $60 Million Series B | Wilson Sonsiniwsgr.com · 2022
- Mirvie Raises $60 Million Funding Round to Shape the Future of Pregnancy Healthbusinesswire.com · 2022



